Glyciglic-MR Tablet is a combination oral antidiabetic medication containing Gliclazide 60 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscles. The extended-release formulation of Glyciglic-MR allows for sustained therapeutic effects, promoting better glycemic control with reduced dosing frequency and improved patient compliance. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target glycemic levels. Glyciglic-MR should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose and HbA1c. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, hematologic abnormalities. Regular follow-up and dose adjustments based on clinical response and tolerability are essential to optimize therapeutic outcomes and minimize potential risks associated with therapy.